

Literaturverzeichnis zum Titelthema: Neu in der Virologie

von Dr. Philipp Steininger, Dr. Klaus Korn, Privatdozentin Dr. Antje Knöll und
Professor Dr. Klaus Überla
Bayerisches Ärzteblatt 3/2025, Seite 64 ff.

RSV

1. Koch J, Berner R, Flasche S, Günther F, Kwetkat A, Lange B, Liese J, Meerpohl J, Röbl-Mathieu M, Sandmann F, Schlager J, Schönfeld V, Tabatabai J, Überla K, Vygen-Bonnet S, Weltermann B, Widders G: Beschluss und wissenschaftliche Begründung zur Empfehlung der STIKO zur spezifischen Prophylaxe von RSV-Erkrankungen mit Nirsevimab bei Neugeborenen und Säuglingen in ihrer 1. RSV-Saison. *Epid Bull* 2024;26:3-29 | DOI 10.25646/12198
2. Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, Zhang T, Abram ME, Leach A, Villafana T, Esser MT. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. *Nat Med.* 2023; 29:1172-1179. doi: 10.1038/s41591-023-02316-5
3. Falman A, Schönfeld V, Flasche S, Günther F, Koch J, Kwetkat A, Lange B, Liese J, Meerpohl J, Röbl-Mathieu M, Sandmann F, Schlager J, Tabatabai J, Überla K, Vygen-Bonnet S, Weltermann B, Widders G, Berner R: Beschluss und Wissenschaftliche Begründung zur Empfehlung der STIKO für eine Standard-impfung gegen Erkrankungen durch Respiratorische Synzytial-Viren (RSV) für Personen ≥ 75 Jahre sowie zur Indikationsimpfung von Personen im Alter von 60 bis 74 Jahren mit Risikofaktoren. *Epid Bull* 2024;32:3-28 | DOI 10.25646/12470
4. Sanders RW, Moore JP. *Cell Host Microbe.* Virus vaccines: proteins prefer prolines. 2021 29: 327-333. DOI 10.1016/j.chom.2021.02.002.

FSME

5. Steininger PA, Bobinger T, Dietrich W, Lee DH, Knott M, Bogdan C, Korn K, Lang R. Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention. *Open Forum Infect Dis.* 2017;26;4(4):ofx204.
6. Steininger P, Ensser A, Knöll A, Korn K. Results of Tick-Borne Encephalitis Virus (TBEV) Diagnostics in an Endemic Area in Southern Germany, 2007 to 2022. *Viruses.* 2023;15(12):2357.
7. Knight A, Pauksens K, Nordmark G, Kumlien E. Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab. *Rheumatology (Oxford)* 2017; 56:855-856.
8. Caracciolo I, Bassetti M, Paladini G, Luzzati R, Santon D, Merelli M, Sabbata GD, Carletti T, Marcello A, D'Agaro P. Persistent viremia and urine shedding of tick-borne encephalitis virus in an infected immunosuppressed patient from a new epidemic cluster in North-Eastern Italy. *J Clin Virol* 2015; 69:48-51.
9. Steininger P, Herbst L, Bihlmaier K, Willam C, Körper S, Schrezenmeier H, Klüter H, Pfister F, Amann K, Weiss S, Krüger DH, Zimmermann R, Korn K, Hofmann J, Harrer T. Fatal Puumala Hantavirus Infection in a Patient with Common Variable Immunodeficiency (CVID). *Microorganisms.* 2023;11(2):283.
10. Owens M, Choe L, Rivera JE, Avila JD. West Nile virus neuroinvasive disease associated with rituximab therapy. *J Neurovirol.* 2020 Aug;26:611-614.

11. Kapadia RK, Staples JE, Gill CM, Fischer M, Khan E, Laven JJ, Panella A, Velez JO, Hughes HR, Brault A, Pastula DM, Gould CV. Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review. *Clin Infect Dis*. 2023 Mar 21;76(6):1142-1148.
12. Grankvist A, Andersson PO, Mattsson M, Sender M, Vaht K, Höper L, Sakiniene E, Trysberg E, Stenson M, Fehr J, Pekova S, Bogdan C, Bloembergen G, Wennerås C. Infections with the tick-borne bacterium "Candidatus Neorhlichia mikurensis" mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases. *Clin Infect Dis* 2014; 58:1716-22.
13. Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR 3rd, Christianson D, Dardick K, Coleman M, Giroto JE, Spielman A. Persistent and relapsing babesiosis in immunocompromised patients. *Clin Infect Dis* 2008; 46:370-6.
14. Robert Koch-Institut (RKI): FSME-Risikogebiete in Deutschland (Stand: Januar 2024). *Epid Bull* 2024;9:3-21.
15. Topp AK, Springer A, Dobler G, Bestehorn-Willmann M, Monazahian M, Strube C. New and Confirmed Foci of Tick-Borne Encephalitis Virus (TBEV) in Northern Germany Determined by TBEV Detection in Ticks. *Pathogens*. 2022;11(2).
16. Friedsam AM, Brady OJ, Pilic A, Dobler G, Hellenbrand W, Nygren TM. Geo-Spatial Characteristics of 567 Places of Tick-Borne Encephalitis Infection in Southern Germany, 2018-2020. *Microorganisms*. 2022;10(3).
17. Ständige Impfkommision: Empfehlungen der Ständigen Impfkommision (STIKO) beim Robert Koch-Institut 2024. *Epid Bull* 2024;4:1- 72.
18. Norbert Wagner, Frauke Assmus, Gabriele Arendt, Erika Baum, Ulrich
19. Baumann, Christian Bogdan, Gerd Burchard, Dirk Föll, Edeltraut Garbe, Jane Hecht, Ulf Müller-Ladner, Tim Niehues, Klaus Überla, Sabine Vygen-Bonnet, Thomas Weinke, Miriam Wiese-Posselt, Michael Wojcinski, Fred Zepp. Impfen bei Immundefizienz. *Bundesgesundheitsbl* 2019 · 62:494–515.
20. Dobler G, Kaier K, Hehn P, Bohmer MM, Kreusch TM, Borde JP. Tick-borne encephalitis virus vaccination breakthrough infections in Germany: a retrospective analysis from 2001 to 2018. *Clin Microbiol Infect*. 2020;26(8):1090 e1097-1090 e1013
21. Grl P, Bestehorn-Willmann M, Zange S, Borde JP, Dobler G, von Buttlar H. Tick-Borne Encephalitis Virus Nonstructural Protein 1 IgG Enzyme-Linked Immunosorbent Assay for Differentiating Infection versus Vaccination Antibody Responses. *J Clin Microbiol*. 2020;58(4).

HIV

21. Robert-Koch-Institut (RKI): HIV-Jahresbericht 2023 (gemeldete Neudiagnosen). *Epid Bull* 2024;40:3-20.
22. Late Presentation Working Groups in EuroSIDA and COHERE. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. *BMC Infect Dis*. 2020 Oct 7;20(1):728.
23. Lauscher P, Hanhoff N, Valbert F, Schewe K, Koegl C, Bickel M, Hoffmann C, Stephan C, Pauli R, Preis S, Neumann A, Wolf E. Socio-demographic and psycho-social determinants of HIV late presentation in Germany - results from the FindHIV study. *AIDS Care*. 2023 Nov;35(11):1749-1759.
24. Bickel M, Hoffmann C, Wolf E, Baumgarten A, Wyen C, Spinner CD, Jäger H, Postel N, Esser S, Mueller M, Stoehr A, Preis S, Klauke S, Schewe K; PROPHET study group of dagnae e.V. High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study. *Infection*. 2020 Jun;48(3):453-461.

25. Sobrino-Vegas P, Moreno S, Rubio R, Viciano P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V; Cohorte de la Red de Investigación en Sida, Spain. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. *J Infect.* 2016 May;72(5):587-96.
26. https://eurotest.org/media/ofqn5mi3/2012-014_chip_losark-tysk_v2.pdf
27. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaud H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med.* 2011 Aug 11;365(6):493-505.
28. Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, Esser S. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. *Infection.* 2016 Apr;44(2):151-8.
29. Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F; PURPOSE 1 Study Team. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. *N Engl J Med.* 2024 Oct 3;391(13):1179-1192.
30. Kelley CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreiber T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. *N Engl J Med.* 2024 Nov 27.